Roth Capital Initiates Coverage On OS Therapies with Buy Rating, Announces Price Target of $7

OS Therapies Incorporated

OS Therapies Incorporated

OSTX

0.00

Roth Capital analyst Adam Walsh initiates coverage on OS Therapies (AMEX: OSTX) with a Buy rating and announces Price Target of $7.